Outer membrane protein F-mediated bacterial bionic vesicle as well as preparation method and application thereof
Through high-pressure homogenization technology and bacterial bionic vesicle technology mediated by outer membrane protein F, the problem of insufficient antigen load of bacterial vesicle is solved, significantly improving the anti-tumor immune response ability, and achieving effective inhibition of tumors.
Patent Information
- Application Number
- CN202310629947.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
The insufficient load of existing bacterial vesicle antigens limits its application prospects in tumor immunotherapy and is difficult to effectively stimulate anti-tumor immune response.
By utilizing high-pressure homogenization technology and outer membrane protein F (OmpF) as a traction protein, the tumor-specific antigen HPV16 E7 is bound to bacterial bionic vesicles (BBV), significantly increasing the load of antigen on the vesicle surface and through recombinant plasmids Construct and induce expression to achieve efficient presentation.
It significantly improves the presentation of tumor antigens on the surface of bacterial bionic vesicles, enhances the anti-tumor immune response ability, can effectively inhibit tumor growth, promote the maturation of BMDCs and lysosomal escape, and enhances CD8+ and IFN-γ+ effector cells. answer.
Smart Images

Figure CN119061041A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and particularly relates to a bacterial bionic vesicle mediated by outer membrane protein F, and a preparation method and application thereof. Background Art
[0002] Tumor is one of the major diseases that endanger human health. In addition to conventional treatments such as surgery, radiotherapy and chemotherapy, tumor immunotherapy has become one of the most promising important clinical strategies, such as monoclonal antibody drugs, cytokine therapy, immune checkpoint blockade (ICB), chimeric antigen receptor T cells (CAR-T), and cancer vaccines, which have shown their own remarkable prospects in clinical treatment or preclinical strategy exploration.
[0003] Tumor vaccines are designed to utilize the body's own immune system to stimulate tumor-specific immune effects. They deliver tumor antigens to antigen-presenting cells (APCs) to stimulate the production of tumor-specific immune effector cells and immune memory cells, thereby effectively inhibiting tumor growth, recurrence, and metastasis. A major design hotspot for tumor vaccines is how to successfully deliver tumor antigens to specific antigen-presenting cells (APCs), stimulate efficient antigen uptake, lysosomal escape, and cross-presentation, thereby promoting cells to present antigens via the MHC-I pathway, while efficiently expressing co-stimulatory molecules and pro-inflammatory cytokines, and achieving effective activation of effector T cells.
[0004] Bacterial vesicles are a new vaccine antigen delivery platform. Their protein lipid membrane structure, nano-sized particle size, self-adjuvant effect, and ability to engineer modified antigens and immune regulatory molecules reveal their unique and powerful immune activation ability. However, their low antigen loading capacity limits their application prospects.
[0005] Therefore, how to further increase the antigen loading capacity of bacterial vesicles and improve their ability to stimulate anti-tumor immune response is a problem that needs to be solved. Summary of the invention
[0006] In view of the problems existing in the prior art, the purpose of the present invention is to provide a bacterial bionic vesicle mediated by outer membrane protein F and a preparation method and application thereof, which significantly improves the loading amount of antigens on the surface of bacterial bionic vesicles and provides an important basis for the development of new vaccines based on bacterial bionic vesicles.
[0007] Based on the previous research foundation of the applicant team, high-pressure homogenization technology is used to adjust the appropriate pressure and gap of the high-pressure homogenizer to achieve the extrusion of biomimetic vesicles (BBV) from the bacterial body. This technology can greatly increase the production of vesicles, and can also achieve the corresponding antigens anchored on the vesicles together with membrane anchored proteins. Tumor antigens or cytokines can be pulled to BBV to varying degrees through proteins such as ClyA and Trx. GroEL is a chaperone protein. Studies have found that the antibiotic imipenem not only promotes the release of Klebsiella pneumoniae outer membrane vesicles (OMVs), but also increases the presentation of GroEL protein on OMVs. Therefore, the inventor tried to compare the expression of GroEL on BBV and OMV in the absence of antibiotics. And compared the situation of GroEL, ClyA, and Trx pulling tumor antigens to the surface of BBV, and found that GroEL did not have much advantage over ClyA and Trx. However, during this process, the inventors noticed a band with a high protein enrichment at 35 kDa on BBV. We speculated that if it could be used as a new traction protein, it might greatly increase the presentation of tumor antigens on BBV. Therefore, the inventors analyzed the band by mass spectrometry and found that it was bacterial outer membrane protein F (OmpF), which is one of the main outer membrane pore proteins in Escherichia coli. Based on this, the inventors provided the following solution of the present invention.
[0008] In order to achieve the purpose of the present invention, the first aspect of the present invention provides a method for preparing bacterial biomimetic vesicles mediated by outer membrane protein F, comprising the following steps:
[0009] Step 1, construction, transformation and expression of recombinant protein of recombinant plasmid:
[0010] Inserting the gene sequences encoding the outer membrane protein OmpF and the tumor-specific antigen HPV16 E7 into a vector plasmid to obtain a recombinant plasmid; transforming the recombinant plasmid into Escherichia coli and culturing it in a culture medium; when the OD600 of the bacterial solution reaches 0.4 to 0.6, adding an inducer to induce the expression of the recombinant protein OmpF-E7, and collecting the bacterial solution after the induction;
[0011] Step 2, preparation of OmpF-E7-BBV:
[0012] The bacterial liquid collected in step 1 is centrifuged, the supernatant is discarded, and the precipitate is resuspended in a buffer to obtain a bacterial suspension. The bacterial suspension is treated by high-pressure homogenization, and the bacteria are driven by ultra-high pressure and squeezed through the cracks to form a membrane component carrying the recombinant protein. The suspension obtained after high-pressure homogenization is centrifuged at 6000g and 4°C for 30min, and the resulting supernatant is centrifuged at 26000rpm and 4°C for 30min. After removing the supernatant, the precipitate is resuspended in HBSS buffer and centrifuged by iodixanol density gradient to obtain purified OmpF-E7-BBV.
[0013] Furthermore, the Escherichia coli used for transformation of the recombinant plasmid in step 1 is an Escherichia coli strain in which its own OmpF is knocked out.
[0014] The second aspect of the present invention provides a bacterial biomimetic vesicle mediated by outer membrane protein F, wherein the bacterial biomimetic vesicle is prepared by the above-mentioned preparation method.
[0015] Furthermore, the particle size of the bacterial biomimetic vesicles ranges from 200 nm to 300 nm, and the dispersion coefficient DPI is 0.18 to 0.25; wherein the loading amount of the recombinant protein OmpF-E7 reaches 40%.
[0016] The third aspect of the present invention provides the application of the bacterial biomimetic vesicles mediated by the outer membrane protein F, and the bacterial biomimetic vesicles are used in the preparation of vaccine drugs for preventing breast cancer.
[0017] Compared with the prior art, the present invention has the following beneficial effects:
[0018] 1. The present application found that the outer membrane protein OmpF was used as a guide sequence to achieve efficient expression of the fusion protein OmpF-E7; and compared with the E7 antigen membrane localization mediated by ClyA, Trx, and GroEL, OmpF can significantly increase the efficient presentation of tumor antigens on the BBV surface (accounting for about 40% of the total protein), solving the key challenge of insufficient antigen loading of the bacterial biomimetic vesicle antigen nano-delivery platform, and providing an important basis for the development of new vaccines based on bacterial biomimetic vesicles;
[0019] 2. The bacterial biomimetic vesicle OmpF-E7-BBV mediated by outer membrane protein F constructed by the present invention improves the ability of existing BBV to stimulate anti-tumor immune response and can effectively inhibit tumor growth; specifically: in vitro experiments have confirmed that OmpF-E7-BBV can promote the high expression of co-stimulatory molecules CD80, CD86, MHCI and MHCII on the surface of BMDCs, and significantly promote the maturation of BMDCs; after OmpF-E7-BBV and BMDCs were co-incubated, the vesicles showed lysosomal escape ability, and with the increase of incubation time, the number of vesicles escaping from lysosomes increased. Tumor model intervention studies have shown that OmpF-E7-BBV significantly inhibited tumor growth, and further immune cell responses showed that antigen-specific CD8+ and IFN-γ+ effector cell responses were enhanced, while immunosuppressive MDSCs (Gr+CD11b+) responses were weakened. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] The present invention will be further described below in conjunction with the accompanying drawings and embodiments:
[0021] Figure 1The figure shows the results of the outer membrane protein OmpF being highly enriched in BBV; A shows the bands analyzed after SDS-PAGE Coomassie Brilliant Blue staining and decolorization, and the protein bands enriched in the red box are OmpF proteins; B shows the results of mass spectrometry identification;
[0022] Figure 2 The results of the test example 1, that the fusion protein OmpF-E7 is efficiently presented on the surface of BBV; A is the analysis band after SDS-PAGE Coomassie Brilliant Blue staining and decolorization, and the band indicated by the arrow is the OmpF-E7 protein; B is the Western blot verification using an anti-E7 protein antibody (1:6000), and the arrow indicates the OmpF-E7 protein; C is "+" and "-" representing different treatment methods for the sample;
[0023] Figure 3 The morphology and particle size distribution results of the bacterial biomimetic vesicle OmpF-E7-BBV in Test Example 1 are shown; wherein A is the particle size of OmpF-E7-BBV; and B is the transmission electron microscopy image of OmpF-E7-BBV;
[0024] Figure 4 This is a result diagram showing the proportion of OmpF-E7 protein in the total vesicle protein described in Test Example 1;
[0025] Figures 5 to 8 They are representative images of lysosomal escape in different groups of Test Example 2 at different time points;
[0026] Fig. 9 It is a result diagram of the bacterial biomimetic vesicle OmpF-E7-BBV promoting the maturation of BMDCs in Test Example 3; wherein, A is a representative flow cytometry diagram and B statistical diagram of OmpF-E7-BBV promoting the maturation of BMDCs and secreting CD80 molecules; C is a representative flow cytometry diagram and D statistical diagram of OmpF-E7-BBV promoting the maturation of BMDCs and secreting CD86 molecules; E is a representative flow cytometry diagram and F statistical diagram of OmpF-E7-BBV promoting the maturation of BMDCs and secreting MHCI molecules; G is a representative flow cytometry diagram and H statistical diagram of OmpF-E7-BBV promoting the maturation of BMDCs and secreting MHCII molecules;
[0027] Fig.10 The results of test example 4 that bacterial biomimetic vesicle OmpF-E7-BBV significantly inhibited the growth of tumors in tumor-bearing mice TC-1; A is a representative photo of tumors in each group taken out on the 32nd day; B is a mouse tumor growth curve; C is a statistical weight of tumors in each group taken out on the 32nd day (n=9); D is a statistical weight of spleens taken out on the 32nd day (n=9);
[0028] Fig.11The results of test example 4, which show that the therapeutic immunity of bacterial biomimetic vesicle OmpF-E7-BBV significantly enhances the anti-tumor cell immune response; wherein, A is a representative flow cytometry graph of mouse spleen lymphocyte MDSC; B is a statistical graph of mouse spleen lymphocyte MDSC (n=6); C is a flow cytometry representative graph of CD8α molecules in mouse spleen lymphocytes; D is a statistical graph of CD8α molecules in mouse spleen lymphocytes (n=6); E is a flow cytometry representative graph of IFN-γ in mouse spleen lymphocytes; F is a statistical graph of IFN-γ in mouse spleen lymphocytes (n=6); G is a flow cytometry representative graph of lymphocyte MDSC in mouse tumor tissue; H is a statistical graph of mouse tumor tissue lymphocyte MDSC (n=6); I is a flow cytometry representative graph of CD8α molecules in mouse tumor tissue lymphocytes; J is a statistical graph of CD8α molecules in mouse tumor tissue lymphocytes. DETAILED DESCRIPTION
[0029] The materials used in the following embodiments of the present invention include:
[0030] (1) Plasmids: The pRSFduet-1 vector plasmid was stored by the Molecular Immunology Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences. The recombinant plasmids OmpF-E7-pRSFduet-1 and GroEL-E7-pRSFduet-1 were synthesized by GenesRay Biotech Co., Ltd. and Suzhou GeneWeiZhi Biotechnology Co., Ltd., respectively.
[0031] The nucleotide sequence of OmpF is:
[0032]
[0033] The nucleotide sequence of E7 is:
[0034] ATGCATGGGGACACTCCTACCCTTCACGAATATATGTTAGATTTGCAGCCAGAAACGACAGATCTGTATTGTTACGAGCAGCTAAATGATAGTAGCGAAGAGGAGGACGAAATTGATGGCCCAGCCGGACAAGCTGAGCCTGATCGC GCTCATTACAACATCGTTACGTTGTTGTAAGTGCGACTCTACACTCCGTCTTTGTGTCCAATCAACGCACGTCGATATCCGCACGCTAGAGGACCTCCTCATGGGCACGTTGGGGATAGTGTGCCCAATTTGTTCCCAAAAGCCG.
[0035] (2) Bacterial strains: Escherichia coli BL21 (DE3) strain was purchased from Takara Biotechnology (Dalian) Co., Ltd.
[0036] (3) Cell line: TC-1 cells were maintained by the Molecular Immunology Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences.
[0037] Based on the previous research content and results, it was found that GroEL-E7-BBV prepared by using chaperone protein GroEL and fusion tumor antigen HPV16 E7 protein had an obvious enriched band at around 35kDa when identified by SDS-PAGE ( Figure 1 A), and then mass spectrometry analysis revealed that the band protein was mainly outer membrane protein F (OmpF) ( Figure 1 (B) OmpF is one of the main outer membrane porins in Escherichia coli, which allows small hydrophilic molecules to diffuse passively on the outer membrane. Some studies have also found that OmpF can also serve as an antigen epitope display system on the surface of bacteria. Therefore, the inventors speculate that OmpF protein has the potential to serve as a traction protein.
[0038] Example
[0039] This embodiment provides a bacterial biomimetic vesicle mediated by outer membrane protein F, and the preparation method thereof comprises the following steps:
[0040] Step 1, construction, transformation and expression of recombinant protein of recombinant plasmid:
[0041] S1, construction of recombinant plasmid
[0042] The gene sequences encoding the outer membrane protein OmpF and the tumor-specific antigen HPV16 E7 were inserted into the vector plasmid pRSFduet-1 to obtain the recombinant plasmid OmpF-E7-pRSFduet-1.
[0043] S2, plasmid transformation
[0044] (1) Dilute the recombinant plasmid OmpF-E7-pRSFduet-1 with pure water to a certain concentration;
[0045] (2) Take 100 μl of E. coli BL21 competent cells, add 1 μl of recombinant plasmid OmpF-E7-pRSFduet-1, mix, and place on ice for 20 min;
[0046] (3) heat shock in a metal bath at 42°C for 42–45 s;
[0047] (4) After placing on ice for 3 min, add 500 μl of sterile LB medium into the tube;
[0048] (5) Place the EP tube at 37°C and incubate on a shaker at 180 rpm for 45 min;
[0049] (6) After centrifugation, discard the supernatant and leave 200 μl. Spread the remaining culture medium evenly on an LB plate containing kanamycin resistance and place it in a 37°C constant temperature incubator for inversion culture overnight.
[0050] S3, induction of recombinant protein expression
[0051] The recombinant bacteria expressing OmpF-E7 were cultured in LB medium containing kanamycin at 30°C with shaking. When the OD600 was about 0.6, they were induced with 1 mmol IPTG for 8 hours, and the bacterial liquid was collected to prepare BBV.
[0052] Step 2, preparation of OmpF-E7-BBV:
[0053] OmpF-E7 protein expression was induced at 30°C and 220 rpm for 8 hours in a total volume of 2L. Samples were taken before and after induction for subsequent identification. After the induction, the bacterial solution was collected and centrifuged (conditions 8000rpm, 4°C) for 30 minutes, the supernatant was discarded, and then the bacteria were resuspended with 200mL HBSS buffer, and then the bacterial suspension was passed through a high-pressure homogenizer (APV-2000), cycled 3 times, about 5 minutes, and the pressure was 1200bar. The resulting suspension was centrifuged at 6000g4°C for 30 minutes, and the resulting supernatant was centrifuged at 26000rpm at 4°C for 30 minutes. After removing the supernatant, the precipitate was resuspended with an appropriate amount of HBSS buffer. Purified OmpF-E7-BBV was obtained by ultracentrifugation with iodixanol OptiPerpTM at 4°C and 130000g for 4 hours.
[0054] Comparative Example
[0055] This comparative example provides a bacterial biomimetic vesicle mediated by a chaperone protein GroEL, and its preparation method is basically the same as the implementation of the bacterial biomimetic vesicle mediated by the outer membrane protein F, except that, in step 1 S1, when constructing a recombinant plasmid, the gene sequence encoding the chaperone protein GroEL and the tumor-specific antigen HPV16 E7 is inserted into the vector plasmid pRSFduet-1 to obtain the recombinant plasmid GroEL-E7-pRSFduet-1.
[0056] The bacterial biomimetic vesicle prepared in this comparative example is GroEL-E7-BBV.
[0057] Test Example 1 - OmpF-E7-BBV antigen loading and morphology determination
[0058] The OmpF-E7-BBV prepared in Example was subjected to SDS-PAGE analysis. The results showed that E7 was loaded on BBV at a high content ( Figure 2 The E7 antibody test proved that the expressed band was E7 protein ( Figure 2 B). Further, in order to identify the location of OmpF-E7 in OmpF-E7-BBV, ClyA-IL-10-BBV was used as a positive control, and OmpF-E7-BBV was treated with proteinase K (PK) and EDTA, and SDS-PAGE analysis was performed. The results showed that OmpF-E7 was completely degraded in BBV treated with PK alone, and BBV treated with EDTA alone had no effect on the OmpF-E7 fusion protein. When BBV was treated with both PK and EDTA, the OmpF-E7 fusion protein was completely degraded ( Figure 2 Middle C), indicating that the E7 protein is presented on the surface of BBV by the outer membrane protein OmpF.
[0059] In order to further understand the properties of OmpF-E7-BBV, the particle size distribution of OmpF-E7-BBV was measured using a particle size scanning analyzer, and it was found that its particle size was about 210 nm ( Figure 3 Middle A). Transmission electron microscopy showed that OmpF-E7-BBV assembled into a complete and uniform nanostructure ( Figure 3 (middle B).
[0060] Image Lab software was used to Figure 2 The bands in the SDS-PAGE results shown were analyzed to obtain the proportion of each band. Figure 4 The results showed that in the OmpF-E7-BBV prepared in the example, the loading amount of the recombinant protein OmpF-E7 reached 40%.
[0061] Test Example 2 - Determination of the lysosomal escape ability of OmpF-E7-BBV
[0062] This test example uses mouse bone marrow-derived dendritic cells (BMDCs). BMDCs were separated and cultured for about 6 days. One day in advance, 1×10 5 The cells were plated in a 6-well plate. BBV, comparative example GroEL-E7-BBV, and example OmpF-E7-BBV were stained with Dio dye (green) and co-incubated with BMDCs cells. The cell nuclei were stained with DAPI (blue). The cells were harvested at 2h, 4h, 6h, and 8h, and the lysosomes were stained with a lysosomal probe (red). Lysosomal escape was then observed using a confocal fluorescence microscope, as shown in Figure 2. Figure 5 As shown in Figure 2, no lysosomal escape was observed in any of the groups at 2 h. Figure 6 As shown in Figure 3, at 4 h, OmpF-E7-BBV in the experimental group had a tendency to escape from lysosomes, while the other groups did not. Figure 7 , Figure 8 It was shown that at 6h and 8h, the number of vesicles internalized and escaped in the experimental group increased.
[0063] This indicates that OmpF-E7-BBV can help tumor antigen E7 escape from lysosomes with the help of the protection of bacterial membrane, thereby improving the level of tumor-specific cellular immune response.
[0064] Test Example 3: Effect of OmpF-E7-BBV on bone marrow-derived dendritic cells
[0065] Immature bone marrow-derived dendritic cells (BMDCs) will transform into a mature state after taking up antigens. The molecules that mark their mature state include CD80, CD86, MHCI, and MHCII. At this time, the ability of BMDCs to process and present antigens will be significantly enhanced, thereby activating T cell effects.
[0066] In this test example, mouse bone marrow-derived dendritic cells (BMDCs) were used. BMDCs were isolated and cultured for about 7 days. 1×10 6 The cells were plated in a 96-well plate, and the OmpF-E7-BBV prepared in the example was added for co-incubation for 6 hours, and LPS was used as a positive control group. Then BMDCs cells were collected for flow cytometry staining. Compared with the control group, OmpF-E7-BBV could significantly promote the expression of BMDCs CD80 ( Fig. 9 AB), CD86( Fig. 9 CD), MHCI ( Fig. 9 EF) and MHCII ( Fig. 9 The expression of GH molecules in the culture medium was analyzed by three replicate wells, and there were significant differences in statistics (****p<0.0001, ***p<0.001, **p<0.01, *p<0.05).
[0067] Test Example 4 - Anti-tumor effect of OmpF-E7-BBV
[0068] In order to explore the effect of OmpF-E7-BBV prepared in the example on the growth of TC-1 tumor in tumor-bearing mice, 1×10 6 TC-1 tumor cells were used to establish a mouse tumor model. The tumor size was monitored regularly. When the tumor grew to 13-18 mm 3 The mice were subcutaneously inoculated with BBV, GroEL-E7-BBV, and OmpF-E7-BBV on the right side of the mouse. The amount of vaccine inoculated per mouse was 20 μg / 100 μl, and the vaccine was inoculated once every 7 days for a total of 3 times. The tumor size was measured and recorded with an electronic vernier caliper every 3 days. Compared with the control group, the tumor inoculated with OmpF-E7-BBV was significantly inhibited ( Fig.10 Middle AB), tumor growth is slow, and statistical analysis of tumor and spleen is significantly different ( Fig.10 CD), indicating that the bacterial biomimetic vesicle OmpF-E7-BBV vaccine prepared in the example has obvious effect on tumor treatment. There is a statistically significant difference (****p<0.0001, ***p<0.001, **p<0.01, *p<0.05).
[0069] In order to further explore the anti-tumor mechanism of OmpF-E7-BBV, the specific anti-tumor effector cell response and immunosuppressive cell response of OmpF-E7-BBV were analyzed by flow cytometry. In this test example, the proliferation of MDSC cells of lymphocytes isolated from mouse spleen and tumor tissue in the above-mentioned mouse tumor model was directly detected by flow cytometry. The results showed that the MDSC cells of the experimental group of mice inoculated with OmpF-E7-BBV in the example were reduced compared with the control group ( Fig.11 Middle A, Fig.11 G), the difference was statistically significant after one-way statistical analysis ( Fig.11 Middle B, Fig.11 The results showed that subcutaneous injection of OmpF-E7-BBV reduced the proliferation of immunosuppressive cells. Cytotoxic T lymphocytes (CTL), an immune effector cell in the tumor, are often used as an important indicator of prognosis in immunotherapy. Flow cytometry was used to detect the proliferation of lymphocytes CD8α, IFN-γ, and CTL cells isolated from mouse tumor tissue and spleen. Fig.11 Medium CF, Fig.11 IJ), and the differences were statistically significant after one-way test analysis (****p<0.0001, ***p<0.001, **p<0.01, *p<0.05).
[0070] The tumor model intervention study in this test case showed that OmpF-E7-BBV induced antigen-specific cellular immune responses and significantly inhibited tumor growth. Further immune cell responses showed that antigen-specific CD8+ and IFN-γ+ effector cell responses were enhanced, while immunosuppressive Gr+CD11b+ cell responses were weakened, achieving anti-tumor immune effects.
[0071] Finally, it should be noted that the above is only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred arrangement scheme, a person skilled in the art should understand that the technical solution of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention.
Claims
1. A method for preparing bacterial biomimetic vesicles mediated by outer membrane protein F, characterized in that: The preparation method comprises the following steps: Step 1, construction, transformation and expression of recombinant protein of recombinant plasmid: Inserting the gene sequences encoding the outer membrane protein OmpF and the tumor-specific antigen HPV16 E7 into a vector plasmid to obtain a recombinant plasmid; transforming the recombinant plasmid into Escherichia coli and culturing it in a culture medium; when the OD600 of the bacterial solution reaches 0.4 to 0.6, adding an inducer to induce the expression of the recombinant protein OmpF-E7, and collecting the bacterial solution after the induction; Step 2, preparation of OmpF-E7-BBV: The bacterial liquid collected in step 1 is centrifuged, the supernatant is discarded, and the precipitate is resuspended in a buffer to obtain a bacterial suspension. The bacterial suspension is treated by high-pressure homogenization, and the bacteria are driven by ultra-high pressure and squeezed through the cracks to form a membrane component carrying the recombinant protein. The suspension obtained after high-pressure homogenization is centrifuged at 6000g and 4°C for 30min, and the resulting supernatant is centrifuged at 26000rpm and 4°C for 30min. After removing the supernatant, the precipitate is resuspended in HBSS buffer and centrifuged by iodixanol density gradient to obtain purified OmpF-E7-BBV.
2. The preparation method according to claim 1, characterized in that: The vector plasmid in step 1 is pRSFduet-1, and the specific steps of transforming the recombinant plasmid OmpF-E7-pRSFduet-1 include: (1) Dilute the recombinant plasmid OmpF-E7-pRSFduet-1 with pure water; (2) Take 100 μl of E. coli BL21 competent cells, add 1 μl of recombinant plasmid, mix, and place on ice for 20 min; (3) heat shock in a metal bath at 42°C for 42–45 s; (4) After placing on ice for 3 min, add 500 μl of sterile LB medium into the EP tube; (5) Place the EP tube at 37°C and incubate on a shaker at 180 rpm for 45 min; (6) After centrifugation, discard the remaining 200 μl of supernatant and evenly spread the remaining culture medium on an LB plate containing kanamycin resistance, and place it in a 37°C constant temperature incubator for inversion culture overnight.
3. The preparation method according to claim 1, characterized in that: The specific steps of expressing the recombinant protein OmpF-E7 in step 1 include: The recombinant bacteria expressing OmpF-E7 were cultured in LB medium containing kanamycin at 30°C with shaking. When OD600 reached 0.4-0.6, they were induced with 1 mmol IPTG for 8 hours and then the bacterial culture was collected.
4. The preparation method according to claim 1, characterized in that: The high-pressure homogenization treatment in step 2 is to pass the bacterial suspension through a high-pressure homogenizer for 3 cycles, each for 5 minutes, with a pressure of 1200 bar.
5. The preparation method according to claim 1 or 2, characterized in that: The E. coli used for the recombinant plasmid transformation in step 1 is an E. coli strain in which its own OmpF is knocked out.
6. A bacterial biomimetic vesicle mediated by outer membrane protein F, characterized in that: The bacterial biomimetic vesicles are prepared by the preparation methods described in claims 1 to 5.
7. The bacterial biomimetic vesicle mediated by outer membrane protein F according to claim 6, characterized in that: The particle size of the bacterial bionic vesicles ranges from 200nm to 300nm, and the dispersion coefficient DPI is 0.18 to 0.25; the loading amount of the recombinant protein OmpF-E7 reaches 40%.
8. The use of bacterial biomimetic vesicles mediated by outer membrane protein F as claimed in claim 6 or 7, characterized in that: The bacterial bionic vesicle is used for preparing a vaccine medicine for preventing breast cancer.
Citation Information
Cited By
BCG (Bacillus Calmette Guerin) bionic vesicles and application thereof in preparation of tumor nano vaccines
CN122326503A
Bionic vesicle of bcg and application thereof in preparation of tumor nano vaccine
CN122326503B
